Summary

Drug Discovery Informatics Market – Scope of Report
TMR’s report on the global drug discovery informatics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug discovery informatics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug discovery informatics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the drug discovery informatics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug discovery informatics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug discovery informatics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug discovery informatics market.

The report delves into the competitive landscape of the global drug discovery informatics market. Key players operating in the global drug discovery informatics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug discovery informatics market profiled in this report.

Key Questions Answered in Global drug discovery informatics Market Report
• What is the sales/revenue generated by drug discovery informatics across all regions during the forecast period?
• What are the opportunities in the global drug discovery informatics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Drug Discovery Informatics Market – Research Objectives and Research Approach
The comprehensive report on the global drug discovery informatics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug discovery informatics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug discovery informatics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Discovery Informatics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug Discovery Informatics Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Discovery Informatics Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Discovery Informatics
6.3.2. Development Informatics
6.4. Market Attractiveness, by Product
7. Global Drug Discovery Informatics Market Analysis and Forecast, by Mode
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mode, 2017–2031
7.3.1. In-house Informatics
7.3.2. Outsourced Informatics
7.4. Market Attractiveness, by Mode
8. Global Drug Discovery Informatics Market Analysis and Forecast, by Function
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Function, 2017–2031
8.3.1. Sequencing and Target Data Analysis
8.3.2. Docking
8.3.3. Lead Generation Informatics
8.3.4. Identification and Validation Informatics
8.3.5. Molecular Modeling
8.3.6. Others
8.4. Market Attractiveness, by Function
9. Global Drug Discovery Informatics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical and Biotechnology Companies
9.3.2. Contract Research Organizations
9.3.3. Others
9.4. Market Attractiveness, by End-user
10. Global Drug Discovery Informatics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Drug Discovery Informatics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Discovery Informatics
11.2.2. Development Informatics
11.3. Market Attractiveness, by Product
11.4. Market Value Forecast, by Mode, 2017–2031
11.4.1. In-house Informatics
11.4.2. Outsourced Informatics
11.5. Market Attractiveness, by Mode
11.6. Market Value Forecast, by Function, 2017–2031
11.6.1. Sequencing and Target Data Analysis
11.6.2. Docking
11.6.3. Lead Generation Informatics
11.6.4. Identification and Validation Informatics
11.6.5. Molecular Modeling
11.6.6. Others
11.7. Market Attractiveness, by Function
11.8. Market Value Forecast, by End-user
11.8.1. Pharmaceutical and Biotechnology Companies
11.8.2. Contract Research Organizations
11.8.3. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Product
11.11.2. By Mode
11.11.3. By Function
11.11.4. By End-user
11.11.5. By Country
12. Europe Drug Discovery Informatics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Discovery Informatics
12.2.2. Development Informatics
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Mode, 2017–2031
12.4.1. In-house Informatics
12.4.2. Outsourced Informatics
12.5. Market Attractiveness, by Mode
12.6. Market Value Forecast, by Function, 2017–2031
12.6.1. Sequencing and Target Data Analysis
12.6.2. Docking
12.6.3. Lead Generation Informatics
12.6.4. Identification and Validation Informatics
12.6.5. Molecular Modeling
12.6.6. Others
12.7. Market Attractiveness, by Function
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Pharmaceutical and Biotechnology Companies
12.8.2. Contract Research Organizations
12.8.3. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Product
12.11.2. By Mode
12.11.3. By Function
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Drug Discovery Informatics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Discovery Informatics
13.2.2. Development Informatics
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Mode, 2017–2031
13.4.1. In-house Informatics
13.4.2. Outsourced Informatics
13.5. Market Attractiveness, by Mode
13.6. Market Value Forecast, by Function, 2017–2031
13.6.1. Sequencing and Target Data Analysis
13.6.2. Docking
13.6.3. Lead Generation Informatics
13.6.4. Identification and Validation Informatics
13.6.5. Molecular Modeling
13.6.6. Others
13.7. Market Attractiveness, by Function
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Pharmaceutical and Biotechnology Companies
13.8.2. Contract Research Organizations
13.8.3. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Product
13.11.2. By Mode
13.11.3. By Function
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Drug Discovery Informatics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Discovery Informatics
14.2.2. Development Informatics
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Mode, 2017–2031
14.4.1. In-house Informatics
14.4.2. Outsourced Informatics
14.5. Market Attractiveness, by Mode
14.6. Market Value Forecast, by Function, 2017–2031
14.6.1. Sequencing and Target Data Analysis
14.6.2. Docking
14.6.3. Lead Generation Informatics
14.6.4. Identification and Validation Informatics
14.6.5. Molecular Modeling
14.6.6. Others
14.7. Market Attractiveness, by Function
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Pharmaceutical and Biotechnology Companies
14.8.2. Contract Research Organizations
14.8.3. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Product
14.11.2. By Mode
14.11.3. By Function
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Drug Discovery Informatics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Discovery Informatics
15.2.2. Development Informatics
15.3. Market Attractiveness, by Product
15.4. Market Value Forecast, by Mode, 2017–2031
15.4.1. In-house Informatics
15.4.2. Outsourced Informatics
15.5. Market Attractiveness, by Mode
15.6. Market Value Forecast, by Function, 2017–2031
15.6.1. Sequencing and Target Data Analysis
15.6.2. Docking
15.6.3. Lead Generation Informatics
15.6.4. Identification and Validation Informatics
15.6.5. Molecular Modeling
15.6.6. Others
15.7. Market Attractiveness, by Function
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Pharmaceutical and Biotechnology Companies
15.8.2. Contract Research Organizations
15.8.3. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Product
15.11.2. By Mode
15.11.3. By Function
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Charles River Laboratories International, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Thermo Fisher Scientific
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. PerkinElmer Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Biogen Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Boehringer Ingelheim GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Insilico Medicine, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. International Business Machines Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Schrödinger, LLC
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Curia Global, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Certara, USA
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview